Related Experiment Video
Updated: Jul 11, 2026
A Robust Discovery Platform for the Identification of Novel Mediators of Melanoma Metastasis
Published on: March 8, 2022
Failure at the effector phase: immune barriers at the level of the melanoma tumor microenvironment
1Departments of Pathology and Medicine, University of Chicago, Chicago, Illinois 60637, USA. tgajewsk@medicine.bsd.uchicago.edu
Abstract:
The clinical investigation of numerous therapeutic cancer vaccine strategies has resulted in relative disappointment. Whereas a minority of patients have indeed experienced clinical benefit, the majority of patients show disease progression even in cases in which induction of functional tumor antigen-specific T-cell responses as measured in the blood is easily detected. This observation has led to interrogation of the tumor microenvironment for potential mechanisms of tumor resistance to the effector phase of the antitumor T-cell response. Poor chemokine-mediated trafficking of effector cells and the action of negative regulatory pathways that inhibit T-cell function have been identified as key limiting factors. Important negative regulatory pathways include T-cell anergy from insufficient B7 costimulation, extrinsic suppression by regulatory T-cell populations, direct inhibition through inhibitory ligands such as PD-L1, and metabolic dysregulation such as through the activity of indoleamine 2,3-dioxygenase. Recognition of these evasion mechanisms has pointed toward new therapeutic approaches for cancer immunotherapy.
Insights
Despite detecting T-cell responses, most cancer vaccine strategies fail. Tumor microenvironment resistance mechanisms, including poor cell trafficking and inhibitory pathways, limit therapeutic effectiveness in cancer immunotherapy.
Area of Science:
- Immunology
- Oncology
- Cancer Research
Background:
- Therapeutic cancer vaccines have shown limited success, with most patients experiencing disease progression despite detectable T-cell responses.
- This suggests that the tumor microenvironment (TME) actively hinders anti-tumor immunity.
Purpose of the Study:
- To investigate the mechanisms of tumor resistance within the TME that limit the efficacy of cancer vaccines.
- To identify key factors contributing to treatment failure in cancer immunotherapy.
Main Methods:
- Analysis of clinical data from cancer vaccine trials.
- Interrogation of the tumor microenvironment for immunosuppressive factors and cellular interactions.
- Evaluation of T-cell function and trafficking within the TME.
Main Results:
- Poor chemokine-mediated trafficking of effector T-cells into tumors is a significant barrier.
- Negative regulatory pathways within the TME, such as T-cell anergy, regulatory T-cells, PD-L1, and indoleamine 2,3-dioxygenase, inhibit T-cell function.
- These mechanisms contribute to tumor resistance despite detectable antigen-specific T-cell responses.
Conclusions:
- Understanding TME-mediated resistance is crucial for improving cancer vaccine efficacy.
- Targeting these inhibitory pathways and improving T-cell trafficking offers promising strategies for future cancer immunotherapy development.
More Related Videos
Related Concept Videos
02:17The Tumor Microenvironment
02:17The Tumor Microenvironment
01:27Tumor Immunotherapy
02:38Mitogens and the Cell Cycle
01:40Cell-mediated Immune Responses
01:27Cytotoxic T Cells-mediated Immune Response
Immunological surveillance is the ability of immune cells to monitor and eliminate infected cells with intracellular pathogens, neoplastically transformed cells, and cells with non-self antigens. Cytotoxic T cells and NK...